Research programme: anti-inflammatory therapeutics - Pulmagen Therapeutics

Drug Profile

Research programme: anti-inflammatory therapeutics - Pulmagen Therapeutics

Alternative Names: ADC 3277; CHI 25243

Latest Information Update: 07 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pulmagen Therapeutics
  • Class Anti-inflammatories
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute asthma; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 02 Feb 2017 Preclinical development is ongoing in United Kingdom (Pulmagen Therapeutics pipeline, February 2017)
  • 03 Sep 2016 Pharmacodynamics data from preclinical studies in Chronic obstructive pulmonary disease presented at the 26th Annual Congress of the European Respiratory Society
  • 01 Jul 2011 Pulmagen Therapeutics signs a service agreement with Argenta
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top